These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 11984077)

  • 1. Life-threatening anaphylactoid reaction to amifostine used with concurrent chemoradiotherapy for nasopharyngeal cancer in a patient with dermatomyositis: a case report with literature review.
    Vardy J; Wong E; Izard M; Clifford A; Clarke SJ
    Anticancer Drugs; 2002 Mar; 13(3):327-30. PubMed ID: 11984077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer.
    Brizel DM; Wasserman TH; Henke M; Strnad V; Rudat V; Monnier A; Eschwege F; Zhang J; Russell L; Oster W; Sauer R
    J Clin Oncol; 2000 Oct; 18(19):3339-45. PubMed ID: 11013273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial.
    Komaki R; Lee JS; Milas L; Lee HK; Fossella FV; Herbst RS; Allen PK; Liao Z; Stevens CW; Lu C; Zinner RG; Papadimitrakopoulou VA; Kies MS; Blumenschein GR; Pisters KM; Glisson BS; Kurie J; Kaplan B; Garza VP; Mooring D; Tucker SL; Cox JD
    Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1369-77. PubMed ID: 15050312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amifostine-induced toxic epidermal necrolysis during radiotherapy: a case report.
    Demiral AN; Yerebakan O; Simşir V; Alpsoy E
    Jpn J Clin Oncol; 2002 Nov; 32(11):477-9. PubMed ID: 12499421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amifostine-induced fever: case report and review of the literature.
    Boehme S; Wilson DB
    Pharmacotherapy; 2004 Jan; 24(1):155-8. PubMed ID: 14740795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase II trial of subcutaneous amifostine and radiation therapy in patients with head-and-neck cancer.
    Anné PR; Machtay M; Rosenthal DI; Brizel DM; Morrison WH; Irwin DH; Chougule PB; Estopinal NC; Berson A; Curran WJ
    Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):445-52. PubMed ID: 17141978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toxicity and compliance of subcutaneous amifostine in patients undergoing postoperative intensity-modulated radiation therapy for head and neck cancer.
    Thorstad WL; Chao KS; Haughey B
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):8-12. PubMed ID: 15726516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of subcutaneous amifostine in minimizing radiation-induced toxicities in patients receiving combined-modality treatment for squamous cell carcinoma of the head and neck.
    Law A; Kennedy T; Pellitteri P; Wood C; Christie D; Yumen O
    Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1361-8. PubMed ID: 17869022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral candidiasis in head and neck cancer patients receiving radiotherapy with amifostine cytoprotection.
    Nicolatou-Galitis O; Sotiropoulou-Lontou A; Velegraki A; Pissakas G; Kolitsi G; Kyprianou K; Kouloulias V; Papanikolaou I; Yiotakis I; Dardoufas K
    Oral Oncol; 2003 Jun; 39(4):397-401. PubMed ID: 12676261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study of 45 cases of nasopharyngeal carcinoma with dermatomyositis.
    Hu WJ; Chen DL; Min HQ
    Am J Clin Oncol; 1996 Feb; 19(1):35-8. PubMed ID: 8554033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: a randomized placebo-controlled phase III study.
    Buentzel J; Micke O; Adamietz IA; Monnier A; Glatzel M; de Vries A
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(3):684-91. PubMed ID: 16243440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amifostine (WR-2721), a cytoprotective agent during high-dose cyclophosphamide treatment of non-Hodgkin's lymphomas: a phase II study.
    De Souza CA; Santini G; Marino G; Nati S; Congiu AM; Vigorito AC; Damasio E
    Braz J Med Biol Res; 2000 Jul; 33(7):791-8. PubMed ID: 10881054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serious adverse effects of amifostine during radiotherapy in head and neck cancer patients.
    Rades D; Fehlauer F; Bajrovic A; Mahlmann B; Richter E; Alberti W
    Radiother Oncol; 2004 Mar; 70(3):261-4. PubMed ID: 15064010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized double-blind trial of amifostine versus placebo for radiation-induced xerostomia in patients with head and neck cancer.
    Lee MG; Freeman AR; Roos DE; Milner AD; Borg MF
    J Med Imaging Radiat Oncol; 2019 Feb; 63(1):142-150. PubMed ID: 30461207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01.
    Movsas B; Scott C; Langer C; Werner-Wasik M; Nicolaou N; Komaki R; Machtay M; Smith C; Axelrod R; Sarna L; Wasserman T; Byhardt R
    J Clin Oncol; 2005 Apr; 23(10):2145-54. PubMed ID: 15800308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic analysis of amifostine as adjunctive support for patients with advanced head and neck cancer: preliminary results from a randomized phase II clinical trial from Germany.
    Bennett CL; Lane D; Stinson T; Glatzel M; Buntzel J
    Cancer Invest; 2001; 19(2):107-13. PubMed ID: 11296615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential of Amifostine for Chemoradiotherapy and Radiotherapy-associated Toxicity Reduction in Advanced NSCLC: A Meta-Analysis.
    Devine A; Marignol L
    Anticancer Res; 2016 Jan; 36(1):5-12. PubMed ID: 26722022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II evaluation of amifostine as an esophageal mucosal protectant in the treatment of limited-stage small cell lung cancer with chemotherapy and twice-daily radiation.
    Arquette M; Wasserman T; Govindan R; Garfield D; Senzer N; Gillenwater H; Socinski M
    Semin Radiat Oncol; 2002 Jan; 12(1 Suppl 1):59-61. PubMed ID: 11917286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized phase III trial of postoperative radiochemotherapy +/- amifostine in head and neck cancer. Is there evidence for radioprotection?
    Vacha P; Fehlauer F; Mahlmann B; Marx M; Hinke A; Sommer K; Richter E; Feyerabend T
    Strahlenther Onkol; 2003 Jun; 179(6):385-9. PubMed ID: 12789464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Life threatening laryngeal toxicity following treatment with combined chemoradiotherapy for nasopharyngeal cancer: a case report with review of the literature.
    Baron-Hay S; Clifford A; Jackson M; Clarke S
    Ann Oncol; 1999 Sep; 10(9):1109-12. PubMed ID: 10572611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.